期刊档案 · 医学-药学
Drug Discovery Today
ISSN 1359-6446 · eISSN 1878-5832 · Elsevier Ltd · ENGLAND · Semimonthly · 创刊 1996
Drug Discovery Today 中科院 医学 2区（2025 年升级版），影响因子 8.58，混合开放获取，APC 约 4,720 美元，近 24 个月 110 篇文章投稿到接收中位 98 天，录用比例较难（社区反馈），2025 年发文 285 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Drug Discovery Today 由 Elsevier Ltd 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Computational Drug Discovery Methods、Pharmaceutical Economics and Policy、Biotechnology and Related Fields 等主题的论文，这 3 个主题约占 28.3%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports. Coverage includes: • Novel therapeutic strategies • High-throughput screening • Therapeutic targets • Combinatorial chemistry, parallel synthesis and library design • Drug delivery • ADME/Tox • Advances in key compound classes and therapeutic areas • Genomics and proteomics • Automation and technology • Virtual chemistry • Informatics • Business strategy • Clinical trials and other aspects of drug discovery.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier.com/conflictsofinterest.Submission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：医学-药学
主编 Stephen L. Carney出版商官网
编委会国家分布：中国大陆 5 位（约 14%）；主要国家 美国 15、英国 7、中国 5、德国 3、新加坡 2（共 35 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Computational Drug Discovery MethodsComputer Science17.6%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance5.4%
- Biotechnology and Related FieldsMedicine5.4%
- Monoclonal and Polyclonal Antibodies ResearchMedicine5.2%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology4.7%
- Human auditory perception and evaluationEngineering4.6%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.4%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics4.1%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊：否综述期刊：是
《新锐期刊分区表》（ 2026年3月发布）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊：是综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 2 区 |
Top 期刊：否综述期刊：是
数据库收录
SCIEScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 8.58LetPub ·
- 影响因子（出版商公布）
- 8.7出版商官网 ·
- CiteScore 2026-06
- 16.8LetPub ·
- CiteScore（出版商公布）
- 16.8出版商官网 ·
- SJR 2026-06
- 1.93LetPub ·
- SNIP 2026-06
- 1.81LetPub ·
- h-index
- 157LetPub ·
- h-index
- 251OpenAlex ·
- i10-index
- 4,114OpenAlex ·
- 两年平均被引
- 8.75OpenAlex ·
- 自引率
- 2.3%LetPub ·
- Gold OA 文章占比
- 34.32%LetPub ·
发文规模
- 年文章数
- 259LetPub ·
逐年发文量 OpenAlex 统计 · 累计 7,793 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 222 | 99 | 210 |
| 2025 | 285 | 132 | 1,761 |
| 2024 | 275 | 127 | 4,875 |
| 2023 | 266 | 95 | 6,416 |
| 2022 | 253 | 104 | 9,031 |
| 2021 | 326 | 127 | 12,675 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
98 天投稿到接收中位数 · P25–P75 70 天 – 165 天
- 接收到上线
- 中位数 4 天（110 篇）
- 投稿到上线
- 中位数 101 天
- 样本
- 110 篇有投稿与接收日期的文章（窗口内共 593 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 平均6.0个月LetPub ·
- 平均录用比例（社区反馈）
- 较难LetPub ·
- 投稿到首次决定
- 4 天出版商官网 ·
- 外审后首次决定
- 38 天出版商官网 ·
- 投稿到接收
- 90 天出版商官网 ·
- 接收到发表
- 5 天出版商官网 ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 4,720 / EUR 4,420 / GBP 3,780 / JPY 585,420 | — | — | |
| 出版商官网 | USD 4,530 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点4 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 1–7 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 图文摘要
- 可选
接收的文章类型6 种
- editorialGuest Editorial articles provide a forum for a personal perspective on contemporary issues and controversies - something you are passionate about or that you th…未说明篇幅
- foundation reviewsFoundation Reviews provide an introduction and comprehensive review of fundamental principles in drug discovery, forming an indispensable educational resource. …未说明篇幅
- guest editorialGuest Editorial articles provide a forum for a personal perspective on contemporary issues and controversies - something you are passionate about or that you th…未说明篇幅
- perspectiveGuest Editorial articles provide a forum for a personal perspective on contemporary issues and controversies - something you are passionate about or that you th…未说明篇幅
- reviewGuest Editorial articles provide a forum for a personal perspective on contemporary issues and controversies - something you are passionate about or that you th…未说明篇幅
- short reviewGuest Editorial articles provide a forum for a personal perspective on contemporary issues and controversies - something you are passionate about or that you th…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具的情况。 模型中文摘要
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
集体署名须在投稿时于标题页声明，提交作者应在投稿系统的“Collaborative Author Groups”中登记该团体。 模型中文摘要
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
所有作者必须披露可能不当影响或偏倚其工作的财务和个人关系，并始终填写声明工具。 模型中文摘要
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 出版伦理
作者必须遵守爱思唯尔出版伦理政策中规定的伦理准则。 模型中文摘要
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
原文 ↗出版商官网 ·- 许可与版权 License options
作者将获得开放获取用户许可选项，建议在选择许可前审查这些选项及资助机构的许可要求。 模型中文摘要
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
本刊开放获取选项请参阅其开放获取信息页面。 模型中文摘要
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
本刊采用单盲同行评审，稿件通常至少送交两名审稿人进行独立专家评估，录用与否由编辑决定。 模型中文摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
作者可按爱思唯尔文章共享政策分享预印本，分享预印本不计作先前发表。 模型中文摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier Ltd
- 出版国家或地区
- ENGLAND
- 出版语言
- English
- 出版周期
- Semimonthly
- 创刊年份
- 1996
- ISSN
- 1359-6446
- 电子版 ISSN
- 1878-5832
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Drug Discovery Today 的常见问题
Drug Discovery Today 是中科院几区期刊？
2025 年升级版分区表中，Drug Discovery Today 为医学 2区，小类 药学 2 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
Drug Discovery Today 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 8.58，CiteScore 为 16.8，h-index 为 251。
Drug Discovery Today 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）110 篇已发表文章登记的日期，投稿到接收的中位数为 98 天（四分位 70–165 天）；投稿社区反馈的平均审稿速度为约 6 个月，平均录用比例反馈为“较难”。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Drug Discovery Today 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：1–7 个；参考文献格式：顺序编码制（按引用顺序编号）；图文摘要：可选。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Drug Discovery Today 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 35 位编委中，中国大陆 5 位（约 14%）；人数最多的国家是 美国（15 位）、英国（7 位）、中国（5 位）。统计按编委会页面列出的机构国家计，仅供参考。
Drug Discovery Today 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Drug Discovery Today 被 SCIE、Scopus 收录。
Drug Discovery Today 是开放获取期刊吗？版面费多少？
Drug Discovery Today 为混合开放获取。选择开放获取发表时APC 约 4,720 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。